Literature DB >> 15798085

Epidermal growth factor activates nuclear factor-kappaB in human proximal tubule cells.

Ulla Häussler1, Götz von Wichert, Roland M Schmid, Frieder Keller, Günter Schneider.   

Abstract

The promotion of cell survival and regeneration in acute renal failure (ARF) is important for the restitution of renal function. Epidermal growth factor (EGF) has been implicated in the regulation of cell proliferation. We provide evidence for a direct link between EGF, nuclear factor-kappaB (NF-kappaB), and cell cycle regulation (cyclin D1). EGF was found to stimulate NF-kappaB-dependent gene transcription and DNA binding. In addition, EGF stimulated cyclin D1 promoter activity as well as cyclin D1 expression. Moreover, inhibition of NF-kappaB caused a pronounced reduction of EGF-induced cyclin D1 promoter activity. Furthermore, both EGF-mediated NF-kappaB activation and cyclin D1 expression were inhibited by coexpression of super IkappaB. Taken together, these data identify NF-kappaB and cyclin D1 as downstream targets of EGF and establish a molecular link between stimulation of EGF via activation of NF-kappaB and cyclin D1 expression in human proximal tubular cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15798085     DOI: 10.1152/ajprenal.00434.2003

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  15 in total

Review 1.  Neutrophil gelatinase-associated lipocalin--an emerging troponin for kidney injury.

Authors:  Prasad Devarajan
Journal:  Nephrol Dial Transplant       Date:  2008-09-22       Impact factor: 5.992

2.  The modified rice αAmy8 promoter confers high-level foreign gene expression in a novel hypoxia-inducible expression system in transgenic rice seedlings.

Authors:  Chung-Shen Wu; Wei-Tin Kuo; Chia-Yu Chang; Jun-Yi Kuo; Yi-Ting Tsai; Su-May Yu; Hsi-Ten Wu; Peng-Wen Chen
Journal:  Plant Mol Biol       Date:  2014-01-21       Impact factor: 4.076

Review 3.  Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury.

Authors:  Prasad Devarajan
Journal:  Biomark Med       Date:  2010-04       Impact factor: 2.851

4.  Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis.

Authors:  Fengyun Dong; Xia Zhou; Changsheng Li; Suhua Yan; Xianming Deng; Zhiqun Cao; Liqun Li; Bo Tang; Thaddeus D Allen; Ju Liu
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

5.  Pressure activates epidermal growth factor receptor leading to the induction of iNOS via NFkappaB and STAT3 in human proximal tubule cells.

Authors:  Nalini V Broadbelt; Jie Chen; Randi B Silver; Dix P Poppas; Diane Felsen
Journal:  Am J Physiol Renal Physiol       Date:  2009-04-29

6.  The role of Sp1 in IL-1beta and H. pylori-mediated regulation of H,K-ATPase gene transcription.

Authors:  Arindam Saha; Charles E Hammond; Monika Gooz; Adam J Smolka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-04       Impact factor: 4.052

Review 7.  NF-kappaB activation in melanoma.

Authors:  Yukiko Ueda; Ann Richmond
Journal:  Pigment Cell Res       Date:  2006-04

Review 8.  Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Kyu Sic You; Yong Weon Yi; Jeonghee Cho; Jeong-Soo Park; Yeon-Sun Seong
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

9.  Decrease in tumor necrosis factor-alpha receptor-associated death domain results from ubiquitin-dependent degradation in obstructive renal injury in rats.

Authors:  Taro Misaki; Tatsuo Yamamoto; Sayuri Suzuki; Hirotaka Fukasawa; Akashi Togawa; Naro Ohashi; Hiroyuki Suzuki; Yoshihide Fujigaki; Toshiaki Oda; Chiharu Uchida; Kyoko Kitagawa; Takayuki Hattori; Masatoshi Kitagawa; Akira Hishida
Journal:  Am J Pathol       Date:  2009-06-18       Impact factor: 4.307

10.  EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.

Authors:  Sarmishtha De; Josephine Kam Tai Dermawan; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.